Skip to main content

42 Result(s)

within N. Moore Remove this filter

previous disabled Page of 3
and

  1. No Access

    Chapter and Conference Paper

    Haemodynamic and Metabolic Effects of Nicergoline in Healthy and Arteritic Patients at Rest or During Exercise

    Nicergoline is a hemisynthetic derivative of ergot alcaloids, which has been shown to have a predominant alpha-1 blocking activity with a slight activity on alpha-2 receptors [8, 15]. This alpha-blocking and, ...

    F. Boismare, N. Moore in Proof of Therapeutical Effectiveness of No… (1985)

  2. No Access

    Chapter and Conference Paper

    Hämodynamische und metabolische Wirkungen von Nicergolin bei Gesunden und Patienten mit arteriellen Erkrankungen in Ruhe und unter Belastung

    Nicergolin ist ein halbsynthetisches Derivat eines Mutterkornalkaloids, bei dem sich eine vorwiegend alpha- 1 -blockierende Aktivität mit einer geringen Aktivität an alpha-2-Rezeptoren zeigen ließ [8, 15]. Die...

    F. Boismare, N. Moore in Therapeutische Wirksamkeitsnachweise bei n… (1985)

  3. No Access

    Article

    Complete atrio-ventricular block after furosemide

    We report a case of nonfatal complete atrio-ventricular (A-V) block after injection of 125 mg of furosemide by a central vena cava catheter. Accidents with this diuretic are very rare but this observation show...

    P. Massari, N. Moore, G. Bonmarchand, E. Moirot, J. M. Droy… in Intensive Care Medicine (1986)

  4. No Access

    Article

    Use of ranitidine in young infants with gastro-oesophageal reflux

    E. Mallet, O. Mouterde, F. Dubois, J. L. Flipo… in European Journal of Clinical Pharmacology (1989)

  5. No Access

    Article

    Evolution of atenolol kinetics when hypothyroidism is corrected

    A single oral dose of atenolol 100 mg was given to 7 hypothyroid patients (4 F, 3 M), before and after correction of hypothyroidism, mean delay 3.5 months (2 to 6.5 months).

    H. Levesque, M. O. Richard, J. Fresel… in European Journal of Clinical Pharmacology (1990)

  6. No Access

    Article

    A low molecular weight heparin decreases plasma aldosterone in patients with primary hyperaldosteronism

    Four patients with primary hyperaldosteronism were treated with nadroparin 4100 or 6150 antiXa IU daily for 4 days. Plasma and urine sodium and potassium, and plasma aldosterone and renin were monitored before...

    N. Cailleux, N. Moore, H. Levesque… in European Journal of Clinical Pharmacology (1992)

  7. No Access

    Article

    Lack of effect of magnesium-aluminium hydroxide on the absorption of theophylline given as a pH-dependent sustained release preparation

    Antacids can modify the pharmacokinetic parameters of sustained-release preparations of theophylline by changing the gastric pH. Though this has been studied with various theophylline/antacid combinations, the...

    J. F. Muir, G. Peiffer, M. O. Richard… in European Journal of Clinical Pharmacology (1993)

  8. No Access

    Chapter and Conference Paper

    Numerical Models of 3-D Galactic Dynamos

    We describe here the results of 3-D numerical simulations of an αω-dynamo in galaxies with differential rotation, small scale turbulence, and a shock wave induced by a stellar density wave. A non-linear quench...

    J. S. Panesar, N. Moore, A. H. Nelson in The Cosmic Dynamo (1993)

  9. No Access

    Article

    Protein binding of digitoxin, valproate and phenytoin in sera from diabetics

    Chronic hyperglycaemia results in glycation of serum albumin and might affect the binding of drugs. The aim of the present study was to compare, using an equilibrium dialysis method, the protein binding of the...

    J. Doucet, J. Fresel, G. Hue, N. Moore in European Journal of Clinical Pharmacology (1993)

  10. No Access

    Article

    In Vitro Serum Binding of Gliclazide in Patients with Type I Diabetes Mellitus

    The aim of this study was to investigate the modifying effect of diabetes on the in vitro serum binding of gliclazide at therapeutic concentrations, and to try to determine the role of albumin glycation. Sera wer...

    Dr J. Doucet, J. Fresel, N. Moore, G. Hue, E. Bercoff in Drug Investigation (1994)

  11. No Access

    Article

    Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability

    Objective: Adverse drug reactions (ADRs) are a major cause of hospital admission and in-hospital morbidity. Departments of internal medicine are at the forefront of this problem. To incr...

    R. Lagnaoui, N. Moore, J. Fach… in European Journal of Clinical Pharmacology (2000)

  12. No Access

    Article

    RHex: A Biologically Inspired Hexapod Runner

    RHex is an untethered, compliant leg hexapod robot that travels at better than one body length per second over terrain few other robots can negotiate at all. Inspired by biomechanics insights into arthropod lo...

    R. Altendorfer, N. Moore, H. Komsuoglu, M. Buehler, H.B. Brown Jr.… in Autonomous Robots (2001)

  13. No Access

    Article

    Comparative Tolerability of Paracetamol, Aspirin and Ibuprofen for Short-Term Analgesia in Patients with Musculoskeletal Conditions: Results in 4291 Patients

    The aim of this blinded, randomised, multicentre study was to compare the tolerability of aspirin, paracetamol and ibuprofen in common pain resulting from musculoskeletal conditions (MSC) in general practice ...

    J-M. Le Parc, E. Van Ganse, N. Moore, R. Wall, H. Schneid… in Clinical Rheumatology (2002)

  14. No Access

    Chapter

    Adverse reactions and their mechanisms from nimesulide

    Nimesulide, like other NSAIDs, exhibits adverse reactions in the major organ systems comprising the upper GI tract, liver, kidney, skin and immune systems. Noteworthy is the fact that this drug has relatively ...

    I. Bjarnason, F. Bissoli, A. Conforti, L. Maiden, N. Moore… in Nimesulide — Actions and Uses (2005)

  15. No Access

    Article

    ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

    F. Gregoire, A. Pariente, F. Haramburu, N. Moore in Drug Safety (2006)

  16. No Access

    Article

    ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

    A. Daveluy, C. Raignoux, G. Miremont-Salamée, N. Moore, F. Haramburu… in Drug Safety (2006)

  17. No Access

    Article

    ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

    A. Bénard-Laribière, H. Géniaux, M. Castel, D. Brissac, C. Lecomte… in Drug Safety (2006)

  18. No Access

    Article

    ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

    P. Bahri, B. Bégaud, N. Moore in Drug Safety (2006)

  19. No Access

    Article

    Poster Presentations

    H. Théophile, G. Miremont-Salamé, N. Moore, F. Haramburu in Drug Safety (2007)

  20. No Access

    Article

    Oral Presentations

    A. Pariente, M. Didailler, P. Avillach, G. G. Miremont-Salamé… in Drug Safety (2007)

previous disabled Page of 3